12.12.16

CONFERENCE CALL TO DISCUSS THE STRATEGIC COLLABORATION WITH ALMIRALL

12.12.16

ALMIRALL AND NUEVOLUTION ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP RORγt INHIBITORS FOR TREATMENT OF DERMATOLOGY DISEASES AND PSORIATIC ARTHRITIS

02.12.16

NUEVOLUTION RECEIVES RESEARCH GRANT AND ENTERS COLLABORATION ON DEVELOPMENT OF NEW TAILORED CANCER THERAPEUTICS

17.11.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FIRST QUARTER 2016/17

11.11.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FIRST QUARTER RELEASE AND WEBCAST

08.11.16

NUEVOLUTION TO PRESENT AT UPCOMING INVESTOR CONFERENCES

04.11.16

NUEVOLUTION APPOINTS REDEYE AS CERTIFIED ADVISER

05.10.16

ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

04.10.16

CONFERENCE CALL TO DISCUSS THE STRATEGIC COLLABORATION WITH AMGEN

04.10.16

NUEVOLUTION ANNOUNCES STRATEGIC COLLABORATION WITH AMGEN IN ONCOLOGY AND NEUROSCIENCE

22.09.16

ORAL PRESENTATION OF PRECLINICAL AND PRELIMINARY TOXICOLOGY DATA ON ITS BET BD1 PROGRAM AT DISCOVERY ON TARGET 2016

16.09.16

PRESENTATION OF PRECLINICAL DATA ON ITS BET BD1 PROGRAM AT DISCOVERY ON TARGET 2016

15.09.16

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2015/16 NOW AVAILABLE

06.09.16

Q4 2015/16 QUARTERLY REPORT WEBCAST AND PRESENTATION

06.09.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2015/16

05.09.16

NOTICE OF ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

29.08.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FOURTH QUARTER RELEASE AND WEBCAST

25.08.16

PRESENTATION OF DISCOVERY DATA FROM THE GRP78 INHIBITOR PROGRAM AT EFMC-ISMC 2016

23.08.16

NUEVOLUTION TO PRESENT AT THE 18TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE

16.08.16

PRESENTATION OF PRECLINICAL DATA FROM RORƴt INVERSE AGONIST PROGRAM AT ICI 2016

01.07.16

EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

01.06.16

NOTICE OF EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

20.05.16

REPLAY OF TWO INVESTOR PRESENTATIONS AVAILABLE

11.05.16

Q3 2015/16 QUARTERLY REPORT WEBCAST AND PRESENTATION

10.05.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS QUARTERLY RESULTS FOR THE THIRD QUARTER 2015/16

06.05.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE THIRD QUARTER RELEASE AND WEBCAST

20.04.16

NUEVOLUTION ANNOUNCES FURTHER TECHNOLOGY ACCESS FEE PAYMENT FROM ITS DRUG DISCOVERY COLLABORATION WITH JOHNSON & JOHNSON INNOVATION

04.03.16

THE EUROPEAN PATENT OFFICE ISSUES FOUR PATENTS TO NUEVOLUTION AB (PUBL)

22.02.16

THE DANISH SØ- OG HANDELSRETTEN ISSUES A DECISION ON SEPARATE QUESTIONS IN THE CASE BETWEEN NUEVOLUTION AND HENRIK PEDERSEN/CHEMGENE HOLDING APS

22.02.16

NUEVOLUTION AB (PUBL) ANNOUNCES MILESTONE PAYMENT FROM BIG PHARMA COLLABORATION

04.02.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS QUARTERLY RESULTS FOR THE SECOND QUARTER 2015/16

04.02.16

QUARTERLY REPORT (Q2 2015/16) WEBCAST

02.02.16

CHANGE IN NUEVOLUTION’S BOARD OF DIRECTORS

26.01.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE SECOND QUARTER RELEASE AND WEBCAST